Cancer Therapy
Liposomal and standard paclitaxel formulations have comparable efficacy
Published in Cancer Weekly, September 28th, 2004
Oncologists in the Netherlands conducted a "study of liposome encapsulated paclitaxel (LEP)" to "define the maximum-tolerated dose (MTD), the recommended dose (RD), the dose-limiting toxicities (DLTs), the pharmacokinetic profiles, and to evaluate preliminarily antitumor effects in patients with refractory solid malignancies."
"LEP was administered as an intravenous (i.v.) infusion over 45 min once every week for 6 out of 8 weeks," explained O. Soepenberg and coauthors at Erasmus Medical Centre in Rotterdam. "Fourteen patients were treated at doses ranging...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-09-28)
More Articles from Cancer Weekly
- Acute Myeloid Leukemia
Genes linked to AML-associated centrosome aberrations identified - Cancer Therapy
Genes causing inherited cancer can help elucidate chemoresistance - Esophageal Adenocarcinoma
Expression of LAT-1 characterized - Glioma Therapy
Radiochemotherapy regimen feasible for preirradiated patients - Lymphoma Therapy
Rituximab with chemotherapy shows promise for splenic MZL treatment - Adverse Drug Effects
Substance P may play role in hypersensitivity reactions induced by paclitaxel - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
